Description
Active Ingredient and Pharmaceutical Form
The primary active substance in Navelbine is Vinorelbine Tartrate, a semi-synthetic vinca alkaloid derivative. Navelbine is available in the form of soft gelatin capsules.
Navelbine is prescribed for the following oncological conditions:
Advanced Breast Cancer
Navelbine is used as a single agent or in combination therapy after the failure of standard treatment options.
Advanced Non-Small Cell Lung Cancer
Navelbine is administered as a single agent or in combination as a first-line treatment.
Dosage and Administration
The recommended dosage of Navelbine is 30 mg/m² administered intravenously over 6 to 10 minutes once a week. Dosage modifications may be necessary based on individual patient response and myelosuppression.
Safety and Effectiveness
Navelbine has demonstrated efficacy in the treatment of the specified cancers. Regular monitoring and appropriate dose adjustments are crucial to manage potential side effects.
Side Effects
The common side effects associated with Navelbine include:
Myelosuppression
Dose hold or reduction may be necessary in case of severe myelosuppression.
Other Side Effects
Fatigue, nausea, and neuropathy may also occur.
Drug Interactions
Navelbine (Vinorelbine Tartrate) has a significant number of known drug interactions, including 70 major, 380 moderate, and 17 minor interactions. Common interacting medications include Abraxane, Advair HFA, Afinitor, Cymbalta, Lyrica, Plavix, and Zofran, among others.
Storage and Handling
Navelbine capsules should be stored at a temperature between 5°C to 30°C (41°F to 86°F), protected from excessive light exposure, and kept in their original packaging. Diluted Navelbine solutions may be used for up to 24 hours under normal room light when stored in polyvinyl chloride bags at the recommended temperature range.
Dietary Considerations
Patients taking Navelbine should be monitored for potential issues such as constipation, bowel obstruction, extravasation, neurologic toxicity, pulmonary toxicity, and embryo-fetal toxicity. Appropriate dietary modifications, such as increased fiber intake, hydration, and the use of stool softeners, may be necessary to mitigate these concerns.
Reviews
There are no reviews yet.